Legend BiotechLEGN 73 EBITDA Margin % is -10.49% as of Mar. 2026. GuruFocus rates LEGN with a GF Score™ of 73/100 and a GF Value™ of $98.47 (Possible Value Trap). The stock has 2 warning signs investors should review. Among 945 Biotechnology companies, Legend Biotech ranks better than 60.95% on this metric.
EBITDA Margin % is calculated as EBITDA divided by its Revenue. Legend Biotech's EBITDA for the
three
months ended in Mar. 2026 was $-32 Mil. Legend Biotech's Revenue for the
three
months ended in Mar. 2026 was $305 Mil. Therefore, Legend Biotech's EBITDA margin for the quarter that ended in Mar. 2026 was -10.49%.
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Legend Biotech EBITDA Margin % Related Terms
Legend Biotech EBITDA Margin % Historical Data
* Premium members only.
The historical data trend for Legend Biotech's EBITDA Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LEGN vs DNTH, XENE, CAI: EBITDA Margin % Comparison
For the Biotechnology subindustry, Legend Biotech's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Legend Biotech EBITDA Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Legend Biotech's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Legend Biotech's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Legend Biotech (LEGN) has a EBITDA Margin % of -10.49% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Legend Biotech and its competitors. According to the industry distribution chart, Legend Biotech ranks #369 out of 945 companies in the Biotechnology industry, placing it in the top 39%.
Is Legend Biotech's EBITDA Margin % too high?
Legend Biotech's current EBITDA Margin % is -10.49%. Based on the distribution chart, Legend Biotech ranks #369 out of 945 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Legend Biotech has a GF Score™ of 73/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Legend Biotech's EBITDA Margin % compare to DNTH and XENE?
According to the Biotechnology industry distribution chart, Legend Biotech ranks #369 out of 945 companies for EBITDA Margin %. This puts Legend Biotech in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Biotechnology company?
A good EBITDA Margin % depends on the Biotechnology industry context. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Legend Biotech and its competitors. Legend Biotech's current EBITDA Margin % is -10.49%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Legend Biotech stock overvalued right now?
Based on GuruFocus' analysis, Legend Biotech (LEGN) is currently considered Possible Value Trap. The stock's GF Value™ is $98.47, compared to a current price of $29.38 — trading 70.2% below its estimated fair value. The current EBITDA Margin % is -10.49%. Legend Biotech's overall GF Score™ is 73/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Legend Biotech (LEGN), the current EBITDA Margin % is -10.49% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Legend Biotech (LEGN) Overvalued in 2026?
Based on GuruFocus' analysis, Legend Biotech stock appears to be undervalued.
The current stock price of $29.38 is trading 70.2% below its estimated GF Value™ of $98.47.
GuruFocus considers Legend Biotech to be Possible Value Trap.
Key valuation signals for LEGN:
EBITDA Margin %: -10.49%
GF Value™: $98.47 vs. price of $29.38 (70.2% below fair value)
No single metric tells the full story. See the LEGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.
73GF Score
Get the complete analysis for LEGN
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LEGN has been successfully added to your 
